Antonio Llinàs

DMPK Director and Principal Scientist- with more than 18 years of research experience in the Pharmaceutical industry transforming Hits into Drugs. Worked in more than 60 projects in Drug Discovery (from early exploratory pre-target selection to candidate selection) and in Early Development projects (from preclinical development to FDA/EMA dossier submission). During these 18 years I’ve worked in multiple departments, therapy areas and targets by both oral and inhaled route: i.e. cardiovascular, metabolism, gastrointestinal, renal, respiratory, lung regeneration, inflammation antivirals and autoimmune, mostly with small molecules but also in the last years with the “New Modalities Drugs” e.g. peptides, Protacs, ASOS, proteins, antibodies, etc... Responsible for the progression, selection and quality (i.e. right pharmacokinetic profile in human) of NCEs up to the Candidate (CD) stage and development compounds, setting up and executing the in vitro and in vivo DMPK strategy in projects (including PK and PK/PD), leading a team of ADME, Biotransformation and Modelling&Simulation Scientists and advising senior management on potential risks of progression of compounds. Extensive Project management and leadership skills with excellent proven track record of leading diverse cross-functional teams (5-15), not only in discovery but also in development, through organisational changes and challenging times. Responsible for setting up the AZ PhysChem Lab in AZ Gothenburg and leading and motivating the DMPK-PhysChem team to deliver robust and cost-effective screening ADME data and ad-hoc assays for LG campaigns and LO projects. Led the global outsourcing DMPK and PhysChem screening activities to different CROs, including in vivo PK. Participation in Drug Discovery collaborations, due diligences, and out- and in-licensing activities. As a Director I have also built and lead many global strategic workstreams defining the strategy and vision of DMPK and Inhaled Product Development functions in AZ and I provide scientific and strategic leadership using strong matrix leadership capabilities and coach, mentor and help the long term development of scientists, while building organizational capability via leading strategic initiatives that contribute to the achievement of Business goals within approved budgets, plans and timelines.

• Appointed member of the organising board of the PhysChem Forum. http://physchem.org.uk/
• Appointed Chairman for the PhysChem Forum
• Appointed Core Member of the Global AZ PhysChem Network (Center of Excellence)
• AZ Science Awards
• Winner of the Innovative Medicines and Early Development Science Awards 2013 for “Design and development of LungSim simulation tool for inhalation PK modelling”
• Winner of the Innovative Medicines and Early Development Science Patent Awards 2014 for “New novel Orally Available RIA Compounds- Oral Segra” U.S. Application N.62/055822
• Winner of the RIA iMED Excellence Award 2015 for “Exceptional delivery under extremely aggressive and unprecedented timelines”
• Referee for the Marie Curie Framework European Programme 7
• Project Evaluator for the Romanian National Research Council
• Editorial Board Member ADMET&DMPK
• Editorial Board Member Scientific World Journal
• Reviewer European Union’s Horizon 2020
• Reviewer European Union’s PREBIST program
• Journal of Medicinal Chemistry Award for the Highly Cited Article of 2012 Oxadiazoles in Medicinal Chemistry.
• Journal of Medicinal Chemistry Award for the Highly Cited Article of 2012 Beyond Size, Ionization State and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion and Toxicity for Druglike Compounds.
• Guest Editor Special Solubility Issue in ADMET&DMPK
• Reviewer of: Crystal Growth&Design, Molecular Pharmaceutics, Journal of Medicinal Chemistry, Journal of Organic Chemistry, Journal of Physical Chemistry, Journal of Chemical Information&Modelling, Drug Discovery Today, Drug Discovery Today: Tecnologies, Journal of Pharmaceutical & Biomedical Analysis, Journal of Pharmaceutical and Biomedical Analysis…

Worked in more than 60 projects across discovery and early development., Participated in numerous in-licensing and due diligence assessments from preclinical through Phase III., Experience outsourcing DMPK studies, including in vivo PK, to CROs., Created the Biopharmaceutics department in IPD.

Innovative Medicines and Early Development Science Award 2013, Innovative Medicines and Early Development Science Patent Award 2014, RIA iMED Excellence Award 2015, Chair and organizing board member, PhysChem Forum (http://physchem.org.uk/), Core Member, Global AZ PhysChem Network, Editorial Board Member, ADMET & DMPK, Scientific World Journal

1. B. Vilanova, J. Frau, A. Llinàs, M. Coll, F. Munoz, and J. Donoso. Δ3-Δ2 isomerization of cephalosporins: the effect of the substituent at the 3-position. Electronic Conference on Heterocyclic Chemistry, June 24-July 22, 1997.

2. M. Coll, J. Donoso, B. Vilanova, J. Frau, A. Llinàs and F. Muñoz. Alkaline Hydrolysis of a β-Lactam Ring. Internet Journal of Chemistry, 1998, 1, 27.

3. A. Llinàs, B. Vilanova , J. Frau, F. Muñoz , J. Donoso, and M. I. Page. Chemical Reactivity of Penicillins and Cephalosporins. Intramolecular Involvement of the Acyl-Amido Side Chain. J. Org. Chem., 1998, 63, Nº24, 9052-9060.

4. M. Coll, J. Frau, B. Vilanova, A. Llinàs J. Donoso and F. Muñoz.Theoretical Study of Proton Transfer Reactions in a β-Lactam Ring. Internet Journal of Chemistry, 1999, 2, 18.

5. J. Frau, M. Coll, B. Vilanova, A. Llinàs J. Donoso and F. Muñoz. Ab initio Study of the chemical reactivity of oxo-β-lactam structure. Internet Journal of Chemistry, 1999, 2, 16.

6. A. Llinàs, J. Donoso, B. Vilanova, J. Frau, F. Muñoz and M.I. Page. Thiol catalysed hydrolysis of benzylpenicillin. J. Chem. Soc., Perkin Trans. 2, 2000, 1521-1525.

7. A. Llinàs, B. Vilanova, F. Muñoz and J. Donoso. The role of a β-proton transfer donor in the degradation of benzylpenicillin. Journal of Molecular Catalysis A, 2001, 175, 3-16.

8. A. Llinàs. Chemical Reactivity of Penicillins and Cephalosporins. Huddersfield (UK). University of Huddersfield 2003. ASIN B001AC7SUK

9. A. Llinàs and M. I. Page. Intramolecular general acid catalysis in the aminolysis of β-lactam antibiotics. Org. Biomol. Chem., 2004, 2, 651-654.

10. A. Llinàs, B. Vilanova and M. I. Page. Thiol-catalysed hydrolysis of cephalosporins and possible rate-limiting amine anion expulsion. J. Phys. Org. Chem., 2004, 17, 521-528.

11. A. Llinàs, N. Ahmed, M. Cordaro, A. P. Laws, J-M. Frere, M. Galleni, R. Silvaggi, J. A. Kelly and M. I. Page. Inactivation of Bacterial DD-Peptidase by β-Sultams. Biochemistry, 2005, 44, 7738-7746.

12. A. Badarau, A. Llinàs, A. Laws, C. Damblon, and M. I. Page. Inhibitors of Metallo–β-Lactamase generated from β-Lactam Antibiotics. Biochemistry, 2005, 44, 8578-8589.

13. A. Llinàs, L. Fàbiàn, J. C. Burley, J. van de Streek and J. M. Goodman. Amodiaquine Dihydrochloride Dihydrate from Laboratory Powder Diffraction Data. Acta Cryst., 2006. E62, o4196-o4199.

14. A. Llinàs, J. C. Burley, K. J. Box, R. C Glen and J. M. Goodman. Diclofenac solubility: independent determination of the intrinsic solubility of three crystal forms. J. Med. Chem. 2007, 50(5), 979-983.

15. A. Llinàs, K. J. Box, J. C. Burley, R. C Glen and J. M. Goodman. A New Method for the Reproducible Generation of Polymorphs: Two Forms of Sulindac with Very Different Solubilities. J. Appl. Cryst. 2007, 40(2), 379-381.

16. D. S. Palmer, A. Llinàs, I. Morao, G. M. Day, J. M. Goodman, R. C. Glen and J. B. O. Mitchell. Predicting Intrinsic Aqueous Solubility by a Thermodynamic Cycle. Mol. Pharm. 2008, 5 (2), 266-279.

17. A. Llinàs, J. C. Burley, T. J. Prior, R. C. Glen, and J. M. Goodman..Concomitant Hydrate Polymorphism in the Precipitation of Sparfloxacin from Aqueous Solution. Special Issue “Facets of Polymorphism in Crystals”. Cryst. Growth & Des. 2008, 8 (1), 114-118.

18. A. Llinàs and J. M. Goodman. Polymorph Control and Selection: Past, Present and Future. Drug Discovery Today. 2008, 13, 198-210.

19. A. Llinàs and R. C. Glen. Vowing each rotatable bond in the molecule, the lowest enthalpy conformer was fully opti-mized and characterized to obtain the global minimum enthalpy conformer for each materi-al investigated. J. Chem. Inf. Model. 2008, 48 (7), 1389-1395.

20. A. Llinàs, R. C. Glen, and J. M. Goodman. Solubility Challenge: Can You Predict Solubilities of Thirty-Two Molecules Using a Database of One Hundred Reliable Measurements?. J. Chem. Inf. Model. 2008, 48, 1289-1303. (most cited article in the last 3 years) http://pubs.acs.org/action/showMostCitedArticles?topArticlesType=recent&journalCode=jci#s8

21. A. Llinàs, A. J. Hopfinger, E. X. Esposito, R. C. Glen, J. M. Goodman. Findings of the Challenge To Predict Aqueous Solubility. J. Chem. Inf. Model. 2009, 49, 1-5.

22. A. Llinàs, J. C. Burley, R. C. Glen, and J. M. Goodman. Crystal Structure of Neutral Anhydrous Naloxone, a Narcotic Antagonist. Cryst. Growth & Des. 2009, 6 (1), 114-118.

23. H. Wan, P. Bold, L.-O. Larsson, J. Ulander, S. Peters, B. Lotberg,A.-L. Ungell, M. Nagard, A. Llinàs. Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model. Current Drug Metabolism 2010, 11(7), 583-594.

24. A. Llinàs and J. M. Goodman. How easy it is to grow single crystals?. J. Chem. Inf. Model. 2010, 38, 314-320

Fabrizio Giordantelo, Laurent Knerr, Nidhal Selmi, Antonio Llinàs. Discovery of N-(1-adamantyl)-2-(4-(alkylpiperazin-1-yl)) acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors. Bioorganic & Medicinal Chemistry Letters 2011, 21, 5557-5561.

26. Y. Yang, O. Engkvist, A. Llinàs, H. Chen. Beyond Size, Ionization State and Lipophilicity: Influence of Molecular Topology on ADMET Properties for drug-like Compounds. J. Med. Chem., 2012, 55 (8), 3667–3677

27. J. Boström, A. Hogner, A. Llinàs, A. T. Plowright and E. Wellner. Oxadiazoles in Medicinal Chemistry. J. Med. Chem., 2012, 55(5), 1817-1830. (Cover and viewpoint article by Klaus Muller in J. Med. Chem. as “The Power of MMPA and a Teaching Lesson in Medicinal Chemistry”)

28. A. Llinàs, J. Boström, K. Granberg, H. Emtenaes, M. Mogemark. N-containing heterocycles as IKAch blockers and their preparation and use for the treatment of IKAch-mediated diseases. Jun 7, 2012, WO 2012074469A1

29. Fabrizio Giordantelo, Laurent Knerr, Nidhal Selmi, Antonio Llinàs.. Discovery of N-[[1-(2-tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor. Bioorganic & Medicinal Chemistry Letters 2013, 23, 119-124

30. Johan Ulander, Fredrik Bergstrom, Ulf Bredberg, Antonio Llinàs. Right metrics at the right time and for the right questions - drug design strategies from virtual screening to optimization and selection of drug-candidates. 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014.

31. Malin Lemurell, Jonas Barlind, Johan Broddefalk, Anders Dahlen, Antonio Llinàs. From lead to candidate drug selection of AZD6642, a 5-lipoxygenase activating protein (FLAP) inhibitor. 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014.

32. Malin Lemurell, Johan Ulander, Susanne Winiwarter, Anders Dahlen, Ojvind Davidsson, Antonio Llinàs. Discovery of AZD6642, an inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the treatment of inflammatory diseases, J. Med. Chem. 2015, 58, 897-911. http://pubs.acs.org/doi/abs/10.1021/jm501531v

33. D.S. Palmer, M. Mislin, M. V. Fedorov, Antonio Llinàs. Fast and General Method to Predict the Physicochemical Properties of Druglike Molecules Using the Integral Equation Theory of Molecular Liquids, Mol. Pharm. 2015, 12(9), 3240-3432. http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00441

34. Antonio Llinàs, R. Barbas, M. Font-Bardia, M. J. Quayle, S. Velaga, R. Prohens. Two New Polymorphic Cocrystals of Zafirlukast: Preparation, Crystal Structure, and Stability Relations. Cryst. Growth Des., 2015, 15(8), 4162-4169. http://pubs.acs.org/doi/abs/10.1021/acs.cgd.5b00744

35. Alex Avdeef, Elisabet Fuguet, Antonio Llinàs, Clara Ràfols, Elisabet Bosch, Gergely Völgyi, Tatjana Verbić, elena Boldyreva, Krisztina Takács-Novák. Equilibrium solubility measurement of ionizable drugs- consensus recommendations for improving data quality, ADMET & DMPK, 2016, 4(2), 117-178. White paper: http://www.pub.iapchem.org/ojs/index.php/admet/article/view/292

36. Antonio Llinàs, Philip Corner, David Berry, James McCabe, Rafael Barbas, Rafel Prohens, Hongwen Du, Hongyu Zhou. Property Prediction and Pharmacokinetic Evaluation of Mixed Stoichiometry Cocrystals of Zafirlukast, a Drug Delivery Case Study, CrystEngComm, 2018, 20 (10), 1346-1351

37. Frank Narjes, Yafeng Xue, Stefan Von Berg, Jesper Malmberg, Antonio Llinàs, Roine Olsson, et al. Potent and Orally Bioavailable Inverse Agonists of RORγt resulting from Structure-Based Design, J. Med. Chem., 2018, 61(17), 7796-7813

38. Cristina Gardelli, Hiroki Wada, Asim Ray, Antonio Llinàs, Igor Sahmovsky, Joakim Tholander, et al. Identification and pharmacological profile of an indane based series of ghrelin receptor full agonists, J. Med. Chem., 2018, 61(14), 5974-5987 https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00322

39. Lena Ripa, Karl Edman, Matthew Dearman, Goran Edreno, Antonio Llinàs, Ramon Hendrickx, Victoria Ullah, et al. Discovery of a novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile, J. Med. Chem., 2018, 61(5), 1785-1790

40. Antonio Llinàs, Rafael Barbas, Merce Font-Bardia, Amir Smailagic, Rafel Prohens. Derisking development by cocrystallization screen of a novel selective inhaled JAK-STAT inhibitor, Cryst. Growth & Design, 2019, 19(1), 403-414

41. Stefan von Berg, Yafeng Xue, Mia Collins, Antonio Llinàs, Roine Olsson, et al. Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2, ACS Med. Chem. Lett., 2019, 10(16), 972-977 https://pubs.acs.org/doi/10.1021/acs.jcim.9b00345

42. Antonio Llinàs and Alex Avdeef. Solubility Challenge Revisited after Ten Years, with Multilab Shake-Flask Data, Using Tight (SD=0.17 log) and Loose (SD=0.62 log) Test Sets, J. Chem. Inf. Model, 2019, 59(6), 3036-3040 https://pubs.acs.org/doi/10.1021/acs.jcim.9b00345

43. Vigneshvari Subramanian, Ekaterina Ratkova, David Palmer, Ola Engkvist, Maxim Fedorov, Antonio Llinàs. Multilevel Models for Solvation Free Energy Predictions Using 3D-RISM Hydration Thermodynamic Descriptors. J. Chem. Inf. Model. 2020, 60(6), 2977–2988 https://doi.org/10.1021/acs.jcim.0c00065

44. Martin Cooper, Antonio Llinàs, Moya Caffrey, Peter Hansen, Hiroki Wada, Asim Ray, Stina Sjödin, et al. Identification and optimization of pyrrolidine derivatives as highly potent Ghrelin receptor full agonist. J. Med. Chem., 2020, 63(17), 9705-9730

45. Antonio Llinàs , Ioana Opriisu and Alex Avdeef. Findings of the second Solubility Challenge to Predict Aqueous Solubility. J. Chem. Inf. Model. 2020, 60(10), 4791-4803

46. Christel Bergström and Antonio Llinàs. Strategies of solubility enhancement and perspectives in solubility measurements of pharmaceutical compounds. ADMET & DMPK, 2020, 8(3), 176-170

47. Flavia Cipicgan, Paul Smith, Jason Crain, Anders Hogner, Leonardo De Maria, Ekaterina Ratkova, Antonio Llinàs. Membrane permeability in cyclic peptides is modulated by core conformations. J. Chem. Inf. Model. 2021, 61(1), 263-269

48. Frank Narjes, Antonio Llinàs, Stefan von Berg, Mia Collins, et al. Discovery of (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide (AZD0284), a potent, selective and orally bioavailable inverse agonists of RORC. Submitted J. Med. Chem.

49. Frank Narjes, Antonio Llinàs, Stefan von Berg, John Jirholt, et al. AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. J. Med. Chem. 2021, 64(8), 13807-13829

50. Antonio Llinàs, Rafael Barbas, Rafel Prohens. The Solid State Landscape of the Sildenafil Drug. J. PharmSci. 2022, 111(4), 1104-1109

51. Jonathan Conn, James W. Carter, Justin Conn, Vigneshvari Subramanian, Andrew Baxter, Antonio Llinàs. Blinded Predictions and Post Hoc Analysis of the Second Solubility Challenge Data: Exploring Training Data and Feature Set Selection for Machine and Deep Learning Models. J. Chem. Inf. Model. 2023, 63(4), 1099-1113

52. Lena ripa, Jenny Sandmark, Glyn Hughes, Igor Shamovsky, Anders Gunnarsson, Julia Johansson, Antonio Llinàs, Mia Collins, et al. Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism. J. Med. Chem. 2023, 66(20), 14188-14207

53. Kalle Sigfridsson, Xiang Zhang and Antonio Llinàs. Case study: cremophor EL-based liquid formulations as simple substitutes for amorphous solid dispersions in early preclinical in vivo studies. J Pharm Pharmacol. 2024 Jul 23:rgae099. doi: 0.1093/jpp/rgae099. Online ahead of print.

54. Sohaib Mahri, Celine Cassiers, Sandra Gracin, Donatienne Tyteca, ..., Antonio Llinàs, Markus Fridén, Rita Vanbeber. Impact of protein aggregation on the immunogenicity of a human monoclonal antibody following pulmonary administration in mice. Int. J. Pharmaceutics 2024, 667(partB), 124880

55. Mia Collin, Rikard Pehrson, Hanna Grindebacke, Agnes Leffler, ..., Antonio Llinàs, et al. RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis. PLOS One 2025, January 16

• A. Llinas, J. Boström, K. Granberg, H. Emtenaes, M. Mogemark. N-containing heterocycles as IKACh blockers and their preparation and use for the treatment of IKACh-mediated diseases. Jun 7, 2012, WO 2012074469A1
• A. Llinas, J. Boström, K. Granberg, H. Emtenaes, M. Mogemark. Compounds and their use as IKACh blockers. Jun 6, 2013, US 20130143858 A1
• A. Llinas, J. Boström, K. Granberg, H. Emtenaes, M. Mogemark. Compounds and their use as IKACh blockers. Jun 7, 2012, US 20120142659 A1
• A. Llinas, L. Ripa, K. Lawitz, K. Edman, M. Lepistö, M. Hemmerling. Preparation of 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators. March 31, 2016, WO2016046260 A1 20160331
• A. Llinas, C. Gardelli, I. Shamovsky, M.E. Cooper, M.V. Caffrey. Patent Application Number PCT/CN2015/082302 filed on the 25th day of June 2015
• A. Llinas, F. Narjes, S. Von Berg, M. Lepistö, R. Olsson, Y. Xue. U.S. Application N.62/193272
• A. Llinas, F. Narjes, S. Von Berg, M. Lepistö, R. Olsson, Y. Xue. U.S. Application N.62/193663

• Experience in outsourcing DMPK, including in vivo PK studies to CROs, I have initiated several external collaborations. These ones are a few with SIGNED contracts
• CIRCE/Univesity Barcelona/University of Sheffield: Virtual and experimental cocrystal screening of Inhaled API
• CIRCE/University of Barcelona/Freeslate: Finding a once daily Budesonide using a new cocrystal HTS approach
• Strathclyde University: Developing of new Computational models to predict the solubility of drug like molecules in biorelevant fluids using both molecular simulation and molecular informatics based approaches. This group has a good track record using Theory of Molecular Liquids and Molecular Dynamics to predict solvation properties and understanding the mechanisms driving the differences in solubilities in different media. Initially we will start with Fassif and Fessif compared to normal phosphate buffer, but if successful I would like to expand it to the lung fluid also. Our collaborators from Strtychlyde include Prof. Maxim Federov, who is the Director of the Supercomputing facility ARCHIE-WeSt (http://www.archie-west.ac.uk/). They usually charge for the use of the facility. But it doesn’t cost us anything
• SIRIUS (now pION): Developing a new SLF. Measure relevant physical and chemical parameters (approx. 30 APIs) under aqueous conditions and in simulated lung fluid media (and its components) which reproduce the biological conditions in the lung, at 37 C and lung pH~6.9.
• KTH: Methodologies established to create simple 3D constructs of the human lung epithelium suitable for particle dissolution studies.
• Université Catholique de Louvain: Confocal microscopic imaging of spray dried particle dispersion and protein aggregation. Assessment of formation of protein aggregates from Spray Dried inhaled formulations.
• IBM: New models to predict physical properties of New Modalities “bRoF”. Membrane permeability in cyclic peptides is modulated by core conformations
• European Research Grants: Secured several highly prestigious European Research Grants , i.e Dr Ekaterian Ratkova, who thanks to her extensive experience in the prediction of PhysChem properties and Biomolecular and supramolecular recognition of drug-like molecules, will give AZ the prediction capabilities needed to move into the unusual drug space of new modalities with confidence.
• University of Barcelona: Develop new Biometic chromatographic systems to predict properties related to biological processes
• University of Bath (UK): Developing new permeability enhancers to increase gut absorption of poorly permeable drugs, i.e. new modalities, macrocycles, protacs, etc..

• Participated and initiated multiple global/cross-functional networks and projects to ensure highest scientific state of the art knowledge and methods across AZ, including:
• Core Member of the Global AZ PhysChem Network (Center of Excellence)
• Core Member of the Inhalation Centre of Excellence (ICE)
• Core Member of Global AZ task force “Critical Review of absorption methodologies and prediction models to improve accuracy of human PK predictions”
• Core Member of the GCN to review the quality of new CDS
• Core Member of the GCL analytical and Structural Chemistry Network
• Core Member of the Intracellular Concentration Platform
• Core Member of the Biomimetic Chromatography PK and safety modelling
• Core Member of the GCL Protacs network
• Core Member of the GCL Protacs CC Strategy network
• Created the Biopharmaceutics team in IPD
• Created the global group LCMSMS for new modalities in IPD
• Co-Leading global IPD-ADD LNP Reduce to Solid (RtS) delivery platform (IPD)
• Chair of the IPD Global Sciences & Technology Steering Committee (IPD)
• Leading the “gut restricted” global workstream (R&I and PharmSci)
• PhysChem methods used nowadays were developed in my group in Lead Generation as part of the Global PhysChem Network
• Initiated a Global AZ cocrystal strategy
• Liased with externalisation and AP to set up, review CRO’s contracts and evaluate new assays, run now externally.
• Engaged the FDA and EMA in adding my solubility white paper to the appendix of the WHO BCS biowaiver guideline
• Initiated implementation of CETSA in AZ Göteborg.
• Supervised & directed several PhDs, PostDocs (externally), AZ Master Students, AZ postDocs and Mentored several graduate students

• Talks&Congress
• I am a regular presenter at academic and pharmaceutical related conferences, with more than 40 presentations and communications to international congress. I am founder and chairman of the organising board of the PhysChem Forum. http://physchem.org.uk/. I am an active reviewer for many of the most important international journals in the fields of Physical-Organic Chemistry, computational Chemistry/modelling and DMPK and ADME/Tox.